Abstract
Lately, the FDA warned that varenicline may increase the risk of myocardial infarction or other cardiovascular events,being higher in patients with prior history.
Objective: To determine an increase in the number of cardiovascular events in a group of patients treated with varenicline vs bupropion.
Material and Methods:
Prospective study with the patients attending our smoking cessation practice in the last 6 months.We analyzed different variables and Cardiovascular events.
This evalution was carried out 3 and 6 months after the treatment initiation which lasted up to 2 months.We carried out a descriptive analysis.
Results:
From a total of 313 patients(175 varenicline;138 bupropion).The treatment with varenicline was more frequent in men who were older, with a main smoking history, diabetes, ischemic heart disease and higher scores in the Richmond test.We observed no significant differences regarding the cardiovascular events in both groups.
Conclusions:
Both drugs have shown the same safety profile for cardiovascular events.
We observed a higher frequency regarding the blood pressure increase.
- © 2012 ERS